title: Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency.
abstract: OBJECTIVE
  To evaluate clinical outcome of patients with limited-stage diffuse large-cell lymphoma (DLCL) treated with three cycles of chemotherapy followed by involved-region irradiation (IRRT).
  
  
  METHODS
  Adults with limited-stage DLCL were treated with brief doxorubicin-containing chemotherapy regimens between 1980 and 1998. IRRT was administered 3 to 4 weeks after the third chemotherapy treatment in a dose equivalent to 30 Gy in 10 fractions.
  
  
  RESULTS
  Three hundred and eight patients (median age, 64 years) were included, and 299 experienced complete remission. After a median follow-up of 86 months, 64 patients developed progressive disease, and 104 patients died (43 from lymphoma, three from toxicity, and 58 from other causes). Actuarial overall and progression-free survival (PFS) rates were, respectively, 80% and 81% at 5 years and 63% and 74% at 10 years. For subgroups identified using the Miller modification of the International Prognostic Index (IPI), the overall survival rates at 5 and 10 years were, respectively, 97% and 89% (no factors), 77% and 56% (one or two factors), and 58% and 48% (three or four factors), and the 5-year and 10-year PFS rates were, respectively, 94% and 89% (no factors), 79% and 73% (one or two factors), and 60% and 50% (three or four factors). Men with testicular presentation, had a definitely inferior outcome.
  
  
  CONCLUSIONS
  Long-term outcome with three cycles of doxorubicin-based chemotherapy and IRRT confirms that this is a successful approach for the majority of patients with limited-stage DLCL. Subgroups with worse prognoses can be identified, and these patients should be offered alternative treatment approaches.
authors.affiliation: Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, Canada V5Z 4E6. tshenkier@bccancer.bc.ca
authors.forename: Tamara N
authors.initials: TN
authors.lastname: Shenkier
authors.forename: Nicholas
authors.initials: N
authors.lastname: Voss
authors.forename: Randall
authors.initials: R
authors.lastname: Fairey
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.forename: Paul
authors.initials: P
authors.lastname: Hoskins
authors.forename: Richard
authors.initials: R
authors.lastname: Klasa
authors.forename: Paul
authors.initials: P
authors.lastname: Klimo
authors.forename: Susan E
authors.initials: SE
authors.lastname: O'Reilly
authors.forename: Simon
authors.initials: S
authors.lastname: Sutcliffe
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Connors
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001955:British Columbia / Q000453:epidemiology; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D016399:Lymphoma, T-Cell; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D017741:Survivors
chemical_list: D004317:Doxorubicin